Growth Metrics

AC Immune (ACIU) Cash from Investing Activities (2016 - 2025)

AC Immune has reported Cash from Investing Activities over the past 10 years, most recently at $20.0 million for Q4 2025.

  • Quarterly Cash from Investing Activities rose 558.45% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.0 million through Dec 2025, up 166.34% year-over-year, with the annual reading at $79.5 million for FY2025, 166.15% up from the prior year.
  • Cash from Investing Activities was $20.0 million for Q4 2025 at AC Immune, down from $25.8 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $46.3 million in Q1 2023 and troughed at -$83.8 million in Q2 2024.
  • The 5-year median for Cash from Investing Activities is -$561917.7 (2021), against an average of -$69004.6.
  • Year-over-year, Cash from Investing Activities soared 8013.88% in 2023 and then crashed 1362.29% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$23.6 million in 2021, then soared by 121.85% to $5.1 million in 2022, then soared by 409.85% to $26.2 million in 2023, then tumbled by 116.64% to -$4.4 million in 2024, then soared by 558.45% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Cash from Investing Activities are $20.0 million (Q4 2025), $25.8 million (Q3 2025), and $28.8 million (Q2 2025).